Core Viewpoint - Dongyang Sunshine Pharmaceutical has been awarded the "Annual Outstanding Biopharmaceutical Enterprise" at the "Technology Empowerment · Capital Breakthrough" sharing session, highlighting its achievements in innovation and research in the biopharmaceutical sector [1][3]. Company Overview - Dongyang Sunshine Pharmaceutical (06887.HK) is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generics, and biosimilars. The company emphasizes innovation, internationalization, and sustainability, driven by independent research and development [3]. - The company has established a comprehensive R&D system over 20 years, employing over 1,100 R&D personnel, including more than 20 foreign and returned experts. It has received the Guangdong Province Innovation Team title six times and holds over 2,500 patents [3][4]. Strategic Focus - The company adheres to "independent innovation" as its core strategy, deepening its "internationalization" efforts while focusing on three key therapeutic areas: infections, chronic diseases, and tumors. It employs diverse technologies, including small molecules, antibodies, small nucleic acids, ADC, and cell therapies [4]. - Dongyang Sunshine has launched three original innovative drugs and has 49 first-class innovative drugs in development, with one nearing market launch and ten in clinical phases II and III. Several pipeline products have "First in class" or "Best in class" potential [4]. Recent Achievements - In 2024, two candidate drugs are expected to achieve external cooperation and licensing agreements, with a total transaction value exceeding $1 billion [4]. - The company is addressing the global challenge of functional cure for hepatitis B with its small nucleic acid drugs and has the only complete independent intellectual property treatment plan for pan-genotype hepatitis C in China [4]. - Dongyang Sunshine's insulin product, Glargine, is set to be approved for sale in the U.S., making it the first Chinese company to market insulin in the U.S. Additionally, its new diabetes drug, Ologliptin, is also nearing approval [4].